Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 17/20 | 0.65 |
| ▸ | JAK1 | P23458 | 3/20 | 0.65 |
| ▸ | BTK | Q06187 | 2/20 | 0.65 |
| ▸ | TEC | P42680 | 1/20 | 0.65 |
| ▸ | TXK | P42681 | 1/20 | 0.65 |
| ▸ | BLK | P51451 | 1/20 | 0.65 |
| ▸ | BMX | P51813 | 1/20 | 0.65 |
| ▸ | ITK | Q08881 | 1/20 | 0.65 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.65 |
| ▸ | HPGDS | O60760 | 1/20 | 0.61 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23408967 | 1.00 | JAK3 (0.65) | JAK3JAK1BTKTECTXK | |
| SCHEMBL23408959 | 1.00 | JAK3 (0.65) | JAK3JAK1BTKTECTXK | |
| SCHEMBL28855720 | 0.85 | JAK3 (0.59) | JAK3JAK1BTKTECTXK | |
| SCHEMBL25068962 | 0.84 | JAK3 (0.61) | JAK3JAK1BTKTECTXK | |
| SCHEMBL25068917 | 0.84 | JAK3 (0.61) | JAK3JAK1BTKTECTXK | |
| SCHEMBL24867427 | 0.82 | JAK3 (0.77) | JAK3JAK1BTKTECTXK | |
| SCHEMBL26095750 | 0.82 | JAK3 (0.77) | JAK3JAK1BTKTECTXK | |
| SCHEMBL1818948 | 0.82 | HPGDS (0.88) | JAK3JAK1BTKTECTXK | |
| SCHEMBL21333438 | 0.81 | JAK3 (0.66) | JAK3JAK1BTKTECTXK | |
| SCHEMBL23221794 | 0.81 | JAK3 (0.66) | JAK3JAK1BTKTECTXK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230055961-A1 | PENTAFLUOROBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | DUNAD THERAPEUTICS LTD. (GB) | 2023-02-23 | — | — | US | disclosed |
| WO-2021099842-A1 | PENTAFLUOROBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO INC. (CA) | 2021-05-27 | — | — | WO | disclosed |
| WO-2021009568-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO, INC. (CA) | 2021-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230055961-A1 | PENTAFLUOROBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | FURIN, PFAS, CFTR | JAK3 584/4885JAK1 1202/4885BTK 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.